Corcept Therapeutics Incorporated · NASDAQ:CORT
Corcept Therapeutics — Technical Presentation (2026)
15 slides from Corcept Therapeutics's technical presentation, Apr 23, 2026
Slide 1: Co-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: MOMENTUM Results
Co-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM Trial Lance A. Sloan,1 Vanita R. Aroda, Deepak L. Bhatt, Robert S. Busch, Dianne S. Cheung, Ralph A. DeFronzo, Bradley Eilerman, Yehuda Handelsman, Mark Kipnes, John C. Parker, Pam R. Taub,
Slide 2: Why Study Hypercortisolism in Individuals With Resistant Hypertension?
Why Study Hypercortisolism in Individuals With Resistant Hypertension? Resistant • A considerable number of individuals with hypertension hypertension have resistant hypertension1 13% • Secondary endocrine causes, such as primary hyperaldosteronism or endogenous hypercortisolism, may contribute to r
Slide 3: How Does Hypercortisolism Impact Blood Pressure?
How Does Hypercortisolism Impact Blood Pressure? Excess cortisol (hypercortisolism) Hypertension 11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; ACE, angiotensin-converting enzyme; ET-1, endothelin 1; MR, mineralocorticoid receptor; mRNA, messenger RNA; NHE3, Na+/H+ exchanger 3; RAAS, renin-angio
Slide 4: Cardiovascular Consequences of Hypercortisolism
Cardiovascular Consequences of Hypercortisolism Physiological impacts of Consequences of excess cortisol in the cortisol cardiovascular system1 ↑ Renal sodium reabsorption Up to 85% 4.5x risk Hypertension1,2 Stroke3 ↑ Blood pressure ↑ Vascular inflammation ↑ Cardiac hypertrophy 2x risk 6x risk Myoca
Slide 5: Prior to MOMENTUM, a robust, US-based study in individuals with rHTN had not been conducted
Prior to MOMENTUM, a robust, US-based study in individuals with rHTN had not been conducted rHTN, resistant hypertension.
Slide 6: MOMENTUM Eligibility Criteria
MOMENTUM Eligibility Criteria1 Key inclusion criteria Key exclusion criteria 18–80 years • White-coat hypertension rHTN based on 2017 AHA criteria: • Non-adherence to BP medications • SBP ≥130 mmHg despite use of ≥3 BP medications • Systemic glucocorticoid exposure (excluding from different classes
Slide 7: Endogenous Hypercortisolism Definition in Individuals With rHTN
Endogenous Hypercortisolism Definition in Individuals With rHTN Post-DST cortisol >1.8 µg/dL and dexamethasone ≥140 ng/dL in a population with common causes of false-positive DSTs excluded Why use the 1-mg DST? Limitations of other tests • The 1-mg DST is convenient and the most • UFC test results a
Slide 8: The MOMENTUM Study
The MOMENTUM Study1 No hypercortisolism (post-DST cortisol ≤1.8 µg/dL) Visit 1 Visit 2 Any time of day ~8 AM Eligibility, consent, history, exam, non-fasting labs (including DST Hypercortisolism Primary Endpoint: Fasted labs (ACTH, glucose, (post-DST cortisol >1.8 µg/dL with aldosterone, PRA, DHEAS)
Slide 9: Primary Endpoint: Hypercortisolism Prevalence
Primary Endpoint: Hypercortisolism Prevalence 27.3% 95% CI: (24.7%, 31.1%) 297/1086 Post-DST cortisol Mean (SD) Normal >1.8 µg/dL (hypercortisolism) Post-DST cortisola, µg/dL 4.2 (3.5) ≤1.8 Dexamethasonea, ng/dL 484.2 (336.8) >140 Post-DST cortisol ≤1.8 µg/dL Adrenal nodules were reported in 24.3% o
Slide 10: Few Differences in Baseline Characteristics
Few Differences in Baseline Characteristics Post-DST cortisol >1.8 µg/dL ≤1.8 µg/dL (hypercortisolism) P-valuea (n=789) (n=297) Age, years, mean (SD) 65.0 (10.9) 66.2 (10.2) NS Female, % 53.9% 43.8% 0.003 • Individuals with Body mass index, kg/m2, mean (SD) 33.5 (7.1) 32.0 (6.9) 0.002 hypercortisoli
Slide 11: Trend Toward More Antihyperglycemic Medications Observed in Those With Hypercortisolism
Trend Toward More Antihyperglycemic Medications Observed in Those With Hypercortisolism 30% Post-DST cortisol ≤1.8 µg/dL * 27% 25% Post-DST cortisol >1.8 µg/dL *** (hypercortisolism) 20% 18% ** 15% 13% 12% 13% * 8% 8% 9% 9% 5% 213 / 88 / 143 / 73 / 63 / 39 / 94 / 59 / 99 / 45 / 60 / 28 / 69 / 14 / 7
Slide 12: Similar Prevalence of Primary Hyperaldosteronism in Individuals With or Without Hypercortisolism
Similar Prevalence of Primary Hyperaldosteronism in Individuals With or Without Hypercortisolism Post-DST cortisol ≤1.8 µg/dL Post-DST cortisol >1.8 µg/dL (hypercortisolism) 19% 17% 14% 12% 134 / 789 36 / 297 153 / 789 43 / 297 PRA <0.6 ng/mL/h and PRA <1.0 ng/mL/h, aldosterone >10 ng/dL aldosterone
Slide 13: Cortisol & Aldosterone Secretion: A Common Occurrence
Cortisol & Aldosterone Secretion: A Common Occurrence 23% Cortisol & Aldosterone Co- secretion Hypercortisolism 27% 297 / 1086 MOMENTUM Hyper- 4% participants Aldosteronism* N=1086 43 / 1086 18% 4% 196 / 1086 254 / 1086 43 / 1086 Participants with Participants with hypercortisolism and hypercortisol
Slide 14: Conclusions
Conclusions • MOMENTUM is the largest study to date assessing the prevalence of hypercortisolism in participants with rHTN. • Demonstrated that the prevalence of hypercortisolism was 27.3%. • MOMENTUM also collected data on markers of primary aldosteronism, another potential secondary cause of rHTN.
Slide 15: Thanks to All Who Contributed to MOMENTUM
Thanks to All Who Contributed to MOMENTUM The study participants and their families The MOMENTUM investigators and their teams • Al Dhaybi, Omar • Cheung, Dianne • Harrison, Alex • Nakhle, Samer • Sloan, Lance • Ali, Abdallah • Christofides, Elena • Hsia, Stanley • Nijmeh, George • Taub, Pam • Ali,